Abstract: Recombinant human follicle-stimulating hormone, rhFSH, is now commonly used in human assistant reproductive technology. However, rhFSH is difficult to be produced by prokaryotic expression system due to its glycosylation, so there are now only two brands of rhFSH in clinics. In the future, it is necessary to develop high expression cell lines to increase rhFSH yield in the process. And the homogeneity of glycosylation of rhFSH will be primarily considered in the production. This review summarizes the advances of the development of rhFSH and its mutants, and lays the foundation for the further research of rhFSH.